文献速递认知障碍与谵妄安宁疗护

痴呆患者临终照护:Medicare Advantage、ACO与传统 Medicare的比较

Dying with dementia in Medicare Advantage, Accountable Care Organizations, or traditional Medicare.
PubMed 文献 · J Am Geriatr Soc · 2021-05-14

该回顾性研究比较了参加Medicare Advantage(MA)、归属责任照护组织(ACO)或传统Medicare(TM)的痴呆死者临终前30天的住院、有创机械通气(IMV)及院内死亡情况。结果显示,与TM相比,MA参保者住院和院内死亡风险更低,IMV使用更少;而ACO归属者与TM无显著差异。

要点

  • MA参保痴呆死者临终前30天住院率20.5%,低于TM的27.9%和ACO的28.1%。
  • 调整后MA参保者住院 odds 为TM的0.72(95%CI 0.70-0.74),ACO为1.05(95%CI 1.02-1.09)。
  • MA参保者院内死亡 odds 为TM的0.78(95%CI 0.75-0.81),ACO为1.02(95%CI 0.96-1.08)。

核心结论

  • 在痴呆死者中,MA参保者比TM参保者接受了更少的高成本且可能负担重的临终照护,而ACO归属者与TM无显著差异。

研究设计与样本

  • 回顾性研究,纳入370,094名痴呆死者,其中93,801名(25.4%)参加MA,39,586名(10.7%)归属ACO,236,707名(63.9%)为TM。
  • 纳入标准为死亡前91至180天内有养老院居住史、存在两项及以上功能障碍、轻至重度认知障碍。

主要发现

  • 临终前30天住院比例:TM 27.9%,ACO 28.1%,MA 20.5%(p ≤ 0.001)。
  • 调整后住院 odds:MA vs TM为0.72(95%CI 0.70-0.74),ACO vs TM为1.05(95%CI 1.02-1.09)。
  • 调整后院内死亡 odds:MA vs TM为0.78(95%CI 0.75-0.81),ACO vs TM为1.02(95%CI 0.96-1.08)。
  • MA参保者IMV使用调整后 odds 为TM的0.80(95%CI 0.75-0.85)。

临床怎么用

  • 对于痴呆临终患者,MA模式可能减少住院和院内死亡,可参考其照护组织方式。
  • ACO模式在减少临终住院方面未显示优势,需政策调整以改善痴呆临终照护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/OBJECTIVE: Medicare Advantage (MA) and Accountable Care Organizations (ACOs) operate under incentives to reduce burdensome and costly care at the end of life. We compared end-of-life care for persons with dementia who are in MA, ACOs, or traditional Medicare (TM). DESIGN, SETTING, AND PARTICIPANTS: Retrospective study of decedents with dementia enrolled in MA, attributed to an ACO, or in TM. Decedents had a nursing home stay between 91 and 180 days prior to death, two or more functional impairments, and mild to severe cognitive impairment. MEASUREMENTS: Hospitalization, invasive mechanical ventilation (IMV) use, and in-hospital death in the last 30 days of life reported in Medicare billing. RESULTS: Among 370,094 persons with dementia, 93,801 (25.4%) were in MA (mean age [SD], 86.9 [7.7], 67.6% female), 39,586 (10.7%) were ACO attributed (mean age [SD], 87.2 [7.6], 67.3% female), and 236,707 (63.9%) were in TM (mean age [SD], 87.0 [7.8], 67.6% female). The proportion hospitalized in the last 30 days of life was higher among TM enrollees (27.9%) and those ACO attributed (28.1%) than among MA enrollees (20.5%, p ≤ 0.001). After adjustment for socio-demographics, cognitive and functional impairments, comorbidities, and Hospital Referral Region, adjusted odds of hospitalization in the 30 days prior to death was 0.72 (95% confidence interval [CI] 0.70-0.74) among MA enrollees and 1.05 (95% CI 1.02-1.09) among those attributed to ACOs relative to TM enrollees. Relative to TM, the adjusted odds of death in the hospital were 0.78 (95% CI 0.75-0.81) among MA enrollees and 1.02 (95% CI 0.96-1.08) for ACO participants. Dementia decedents in MA had a lower likelihood of IMV use (adjusted odds ratio 0.80, 95% CI 0.75-0.85) compared to TM. CONCLUSIONS: Among decedents with dementia, MA enrollees but not decedents in ACOs experienced less costly and potentially burdensome care compared with those with TM. Policy changes are needed for ACOs.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Teno JM, Keohane LM, Mitchell SL, et al. Dying with dementia in Medicare Advantage, Accountable Care Organizations, or traditional Medicare. J Am Geriatr Soc. 2021. PMID: 33989430. doi:10.1111/jgs.17225

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。